2020 Q4 Form 10-K Financial Statement
#000119312521102551 Filed on March 31, 2021
Income Statement
| Concept | 2020 Q4 | 2019 Q4 |
|---|---|---|
| Revenue | $0.00 | |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | ||
| YoY Change | ||
| % of Gross Profit | ||
| Research & Development | ||
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | ||
| YoY Change | ||
| % of Gross Profit | ||
| Operating Expenses | $4.400M | |
| YoY Change | ||
| Operating Profit | -$17.63K | |
| YoY Change | ||
| Interest Expense | $0.00 | |
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | -$4.400M | |
| YoY Change | ||
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$4.400M | -$17.63K |
| YoY Change | 24856.04% | |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$42.51K | |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q4 | 2019 Q4 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $92.35M | |
| YoY Change | ||
| Cash & Equivalents | $92.35M | $67.60M |
| Short-Term Investments | $0.00 | |
| Other Short-Term Assets | $299.0K | |
| YoY Change | ||
| Inventory | ||
| Prepaid Expenses | $7.830M | |
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $189.8M | $0.00 |
| YoY Change | ||
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $2.078M | |
| YoY Change | ||
| Goodwill | $1.200M | |
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $828.1M | |
| YoY Change | ||
| Other Assets | $8.885M | |
| YoY Change | ||
| Total Long-Term Assets | $77.47M | $100.3K |
| YoY Change | 77102.88% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $189.8M | $0.00 |
| Total Long-Term Assets | $77.47M | $100.3K |
| Total Assets | $267.3M | $100.3K |
| YoY Change | 266230.5% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | ||
| YoY Change | ||
| Accrued Expenses | $4.935M | $0.00 |
| YoY Change | ||
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $800.0K | |
| YoY Change | ||
| Long-Term Debt Due | $20.80M | |
| YoY Change | ||
| Total Short-Term Liabilities | $164.2M | $118.0K |
| YoY Change | 139103.4% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $106.4M | |
| YoY Change | ||
| Other Long-Term Liabilities | $13.12M | |
| YoY Change | ||
| Total Long-Term Liabilities | $119.5M | |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $164.2M | $118.0K |
| Total Long-Term Liabilities | $119.5M | |
| Total Liabilities | $432.7M | $118.0K |
| YoY Change | 366664.71% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.029B | -$17.63K |
| YoY Change | 5836108.95% | |
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | $0.00 | |
| YoY Change | ||
| Treasury Stock Shares | 0.000 shares | |
| Shareholders Equity | -$617.1M | $0.00 |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $267.3M | $100.3K |
| YoY Change | 266230.5% |
Cashflow Statement
| Concept | 2020 Q4 | 2019 Q4 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$4.400M | -$17.63K |
| YoY Change | 24856.04% | |
| Depreciation, Depletion And Amortization | ||
| YoY Change | ||
| Cash From Operating Activities | -$1.130M | -$17.63K |
| YoY Change | 6309.17% | |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | ||
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | |
| YoY Change | ||
| Cash From Investing Activities | $0.00 | |
| YoY Change | ||
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 29.00M | 17.63K |
| YoY Change | 164383.01% | |
| NET CHANGE | ||
| Cash From Operating Activities | -1.130M | -17.63K |
| Cash From Investing Activities | 0.000 | |
| Cash From Financing Activities | 29.00M | 17.63K |
| Net Change In Cash | 27.87M | 0.000 |
| YoY Change | ||
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$1.130M | -$17.63K |
| Capital Expenditures | ||
| Free Cash Flow | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q4 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P5Y | |
| CY2020 | ipoc |
Warrants And Rights Outstanding Exercisable Term From Closing Of Public Offering
WarrantsAndRightsOutstandingExercisableTermFromClosingOfPublicOffering
|
P12M | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
0 | |
| CY2020 | ipoc |
Threshold Period For Filling Registration Statement After Business Combination
ThresholdPeriodForFillingRegistrationStatementAfterBusinessCombination
|
P15D | |
| CY2020Q4 | ipoc |
Accrued Offering Costs Current
AccruedOfferingCostsCurrent
|
0 | |
| CY2019Q4 | ipoc |
Accrued Offering Costs Current
AccruedOfferingCostsCurrent
|
100346 | |
| CY2020 | ipoc |
Threshold Period For Filing Registration Statement Within Number Of Days Of Business Combination
ThresholdPeriodForFilingRegistrationStatementWithinNumberOfDaysOfBusinessCombination
|
P60D | |
| CY2020 | ipoc |
Class Of Warrant Or Right Redemption Of Warrants Or Rights Threshold Consecutive Trading Days
ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays
|
P30D | |
| CY2020Q4 | ipoc |
Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price
ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice
|
18.00 | |
| CY2020Q4 | ipoc |
Advance From Related Party
AdvanceFromRelatedParty
|
193137 | |
| CY2020Q4 | ipoc |
Class Of Warrant Or Right Exercisable For Cash
ClassOfWarrantOrRightExercisableForCash
|
0 | |
| CY2020Q4 | ipoc |
Deferred Underwriting Fees
DeferredUnderwritingFees
|
0.35 | |
| CY2020Q4 | ipoc |
Proceeds From Refund Of Underwriting Discount
ProceedsFromRefundOfUnderwritingDiscount
|
28980000 | |
| CY2020 | ipoc |
Underwriting Discount Percentage
UnderwritingDiscountPercentage
|
0.10 | |
| CY2019Q4 | ipoc |
Advance From Related Party
AdvanceFromRelatedParty
|
17631 | |
| CY2020 | ipoc |
Refunds From Underwriting Discount
RefundsFromUnderwritingDiscount
|
1440000 | |
| CY2020 | us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
2898000 | |
| CY2020Q4 | us-gaap |
Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
|
27999990 | |
| CY2020Q2 | ipoc |
Sponsor Monthly Fee Payable
SponsorMonthlyFeePayable
|
10000 | |
| CY2020Q4 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
250000 | |
| CY2019Q4 | us-gaap |
Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
|
0 | |
| CY2020 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
38533333 | |
| CY2020Q4 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
806208 | |
| CY2020 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
| CY2020 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2019Q4 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
0 | |
| CY2020 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001801170 | |
| CY2020 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
33933978 | |
| CY2020 | ipoc |
Proceeds From Investors In Connection With Business Combination
ProceedsFromInvestorsInConnectionWithBusinessCombination
|
95999990 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
117977 | |
| CY2020Q4 | ipoc |
Deferred Underwriting Fee Payable Noncurrent
DeferredUnderwritingFeePayableNoncurrent
|
28980000 | |
| CY2019Q4 | ipoc |
Deferred Underwriting Fee Payable Noncurrent
DeferredUnderwritingFeePayableNoncurrent
|
0 | |
| CY2020 | ipoc |
Repayment Of Investors Funds In Connection With Business Combination
RepaymentOfInvestorsFundsInConnectionWithBusinessCombination
|
-68000000 | |
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | ipoc |
Interest Income On Marketable Securities Held In Trust Account
InterestIncomeOnMarketableSecuritiesHeldInTrustAccount
|
0 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
62913978 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
0 | |
| CY2020 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2020 | |
| CY2020 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2019Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17631 | |
| CY2020 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
| CY2020 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
TN | |
| CY2019Q4 | ipoc |
Deferred Offering Costs Included In Accrued Offering Costs
DeferredOfferingCostsIncludedInAccruedOfferingCosts
|
100346 | |
| CY2019Q4 | us-gaap |
Profit Loss
ProfitLoss
|
-17631 | |
| CY2020 | ipoc |
Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
|
28980000 | |
| CY2020 | ipoc |
Initial Public Offering Costs
InitialPublicOfferingCosts
|
44156346 | |
| CY2020 | ipoc |
Underwriting Fees
UnderwritingFees
|
14400000 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
117977 | |
| CY2020Q4 | us-gaap |
Other Deferred Costs Net
OtherDeferredCostsNet
|
776346 | |
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | ipoc |
Cash And Marketable Securities Held In Trust Account
CashAndMarketableSecuritiesHeldInTrustAccount
|
828117255 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q2 | ipoc |
Class Of Warrant Or Right Numbers Issued
ClassOfWarrantOrRightNumbersIssued
|
10933333 | |
| CY2020Q2 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
10.00 | |
| CY2020Q2 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
82800000 | |
| CY2020Q4 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
10.00 | |
| CY2020 | ipoc |
Additional Purchase Of Underwriting Shares
AdditionalPurchaseOfUnderwritingShares
|
10800000 | |
| CY2019Q4 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17631 | |
| CY2019Q4 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
17631 | |
| CY2020 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
82800000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2019Q4 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
17631 | |
| CY2020Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
11.50 | |
| CY2020 | us-gaap |
Temporary Equity Net Income
TemporaryEquityNetIncome
|
-111486 | |
| CY2020Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
78727446 | |
| CY2020 | ipoc |
Interest Income On Marketable Securities Held In Trust Account
InterestIncomeOnMarketableSecuritiesHeldInTrustAccount
|
117255 | |
| CY2019Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17631 | |
| CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6862095 | |
| CY2019Q4 | ipoc |
Formation And Operating Costs
FormationAndOperatingCosts
|
17631 | |
| CY2020 | ipoc |
Formation And Operating Costs
FormationAndOperatingCosts
|
6862095 | |
| CY2020 | ipoc |
Class Of Warrant Or Right Numbers Issued
ClassOfWarrantOrRightNumbersIssued
|
10933333 | |
| CY2020 | ipoc |
Units Issued During Period Shares New Issues
UnitsIssuedDuringPeriodSharesNewIssues
|
82800000 | |
| CY2020 | ipoc |
Underwriting Fee Deferred
UnderwritingFeeDeferred
|
28980000 | |
| CY2020 | ipoc |
Change In Ordinary Shares Possible Redemption Value
ChangeInOrdinarySharesPossibleRedemptionValue
|
-6744844 | |
| CY2020 | ipoc |
Initial Classification Of Ordinary Shares Subject To Possible Redemption
InitialClassificationOfOrdinarySharesSubjectToPossibleRedemption
|
795251020 | |
| CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
28003240 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
858230358 | |
| CY2020 | us-gaap |
Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
|
776346 | |
| CY2020 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
300000 | |
| CY2020 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
1106208 | |
| CY2020 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
17631 | |
| CY2020 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
193137 | |
| CY2020 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
16400000 | |
| CY2020 | ipoc |
Proceeds From Sale Of Units Net Of Underwriting Discounts Paid
ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountsPaid
|
813600000 | |
| CY2020 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
25000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-828000000 | |
| CY2020 | ipoc |
Payments To Acquire Investments To Be Held In Trust Account
PaymentsToAcquireInvestmentsToBeHeldInTrustAccount
|
828000000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2227118 | |
| CY2020 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
4934643 | |
| CY2020 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
299666 | |
| CY2020 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
117255 | |
| CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
-6744840 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020 | dei |
Document Type
DocumentType
|
10-K | |
| CY2020 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
| CY2020 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2020 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2020 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-12-31 | |
| CY2020 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2020 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
| CY2020 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
| CY2020Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
38533271 | |
| CY2020Q2 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
828000000 | |
| CY2021Q1 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
10.00 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4934643 | |
| CY2020 | ipoc |
Sponsor Monthly Fee Payable
SponsorMonthlyFeePayable
|
80000 | |
| CY2020 | dei |
Entity Registrant Name
EntityRegistrantName
|
CLOVER HEALTH INVESTMENTS, CORP. /DE | |
| CY2020 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2020 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2020 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2020 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2020 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
28003240 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
0 | |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
299666 | |
| CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
0 | |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
28302906 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
0 | |
| CY2020Q4 | ipoc |
Deferred Offering Cost
DeferredOfferingCost
|
0 | |
| CY2019Q4 | ipoc |
Deferred Offering Cost
DeferredOfferingCost
|
100346 | |
| CY2019Q4 | ipoc |
Cash And Marketable Securities Held In Trust Account
CashAndMarketableSecuritiesHeldInTrustAccount
|
0 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
856420161 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
100346 | |
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
11760012 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
0 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-6762471 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-17631 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5000007 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-17631 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
856420161 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
100346 | |
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
783843654 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
16400000 | |
| CY2020 | ipoc |
Ordinary Shares Subject To Possible Redemption Value
OrdinarySharesSubjectToPossibleRedemptionValue
|
788506176 | |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6744840 | |
| CY2019Q4 | ipoc |
Stock Issued During Period Value Class B Shares New Issue
StockIssuedDuringPeriodValueClassBSharesNewIssue
|
0 | |
| CY2020 | ipoc |
Stock Issued During Period Value Class B Shares New Issue
StockIssuedDuringPeriodValueClassBSharesNewIssue
|
25000 | |
| CY2020 | ipoc |
Class B Shares Cancelled During Period Value
ClassBSharesCancelledDuringPeriodValue
|
0 | |
| CY2020 | ipoc |
Deferred Offering Costs Included In Accrued Offering Costs
DeferredOfferingCostsIncludedInAccruedOfferingCosts
|
0 | |
| CY2020Q2 | dei |
Entity Public Float
EntityPublicFloat
|
925704000 | |
| CY2020 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family: "times new roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-align: justify;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: "times new roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: justify;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: "times new roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: justify;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2020 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;;text-align:justify;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk</div></div></div></div> <div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;;text-align:justify;"><div style="font-family: "times new roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times, may exceed the Federal Depository Insurance Coverage of $250,000 per account. The Company has not experienced losses on this account, and management believes the Company is not exposed to significant risks on such account.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> |
